Literature DB >> 6518345

Energy conservation by nisoldipine in ischaemic heart.

J W De Jong, T Huizer, J G Tijssen.   

Abstract

We studied the effect of the calcium entry blocker nisoldipine on ATP catabolism in the rat heart, perfused according to Langendorff. Even 1 nM nisoldipine induced vasodilatation; concentrations of 30 nM and higher caused significant negative inotropy. The drug had a very strong affinity for silicon rubber tubing. Myocardial ischaemia was induced by lowering the perfusion pressure, which reduced flow without nisoldipine by 85%. The efflux of purine nucleosides and oxypurines rose 14 fold. Nisoldipine reduced this efflux of ATP catabolites dose-dependently. The highest concentration, 300 nM, suppressed ischaemic purine production completely. The action of the drug was antagonized by an increase in Ca2+-concentration in the perfusion fluid. We also showed the protective effect of nisoldipine on adenine nucleotides in freeze-clamped hearts. A concentration of 20 nM partially prevented the reduction of ATP and adenylate energy charge due to ischaemia. We conclude that relatively low doses of nisoldipine effectively prevent ATP breakdown in ischaemic rat heart.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6518345      PMCID: PMC1986981          DOI: 10.1111/j.1476-5381.1984.tb16535.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  Sephadex-induced reduction of coronary flow in the isolated rat heart: a model for ischemic heart disease.

Authors:  H Stam; J W De Jong
Journal:  J Mol Cell Cardiol       Date:  1977-08       Impact factor: 5.000

2.  Myocardial protection by calcium antagonist drugs.

Authors:  A J Drake-Holland; M I Noble
Journal:  Eur Heart J       Date:  1983-11       Impact factor: 29.983

3.  Inhibiting effect of diltiazem on intracellular Ca2+ release in vascular smooth muscle.

Authors:  K Saida; C van Breemen
Journal:  Blood Vessels       Date:  1983

4.  Uptake of [3H]nitrendipine into cardiac and smooth muscles.

Authors:  D C Pang; N Sperelakis
Journal:  Biochem Pharmacol       Date:  1983-05-15       Impact factor: 5.858

5.  Simultaneous determination of myocardial adenine nucleotides and creatine phosphate by high-performance liquid chromatography.

Authors:  E Harmsen; P P de Tombe; J W de Jong
Journal:  J Chromatogr       Date:  1982-06-11

6.  Myocardial xanthine oxidase/dehydrogenase.

Authors:  B Schoutsen; J W De Jong; E Harmsen; P P De Tombe; P W Achterberg
Journal:  Biochim Biophys Acta       Date:  1983-07-14

7.  Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Nisoldipine, Bay k 5552).

Authors:  S Kazda; B Garthoff; H Meyer; K Schlossmann; K Stoepel; R Towart; W Vater; E Wehinger
Journal:  Arzneimittelforschung       Date:  1980

8.  Hemodynamic effects of the new vasodilator drug Bay k 5552 in man.

Authors:  A Vogt; K L Neuhaus; H Kreuzer
Journal:  Arzneimittelforschung       Date:  1980

9.  Nifedipine reduces adenine nucleotide breakdown in ischemic rat heart.

Authors:  J W De Jong; E Harmsen; P P De Tombe; E Keijzer
Journal:  Eur J Pharmacol       Date:  1982-06-16       Impact factor: 4.432

10.  Hypoxanthine production by ischemic heart demonstrated by high pressure liquid chromatography of blood purine nucleosides and oxypurines.

Authors:  E Harmsen; J W de Jong; P W Serruys
Journal:  Clin Chim Acta       Date:  1981       Impact factor: 3.786

View more
  9 in total

1.  Protection of human, rat, and guinea-pig atrial muscle by mioflazine, lidoflazine, and verapamil against the destructive effects of high concentrations of Ca2+.

Authors:  U Ravens; G S Liu; G Vandeplassche; M Borgers
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

2.  Effects of felodipine on the ischemic heart: insight into the mechanism of cytoprotection.

Authors:  R Ferrari; A Cargnoni; P Bernocchi; G Gaia; M Benigno; E Pasini; P Pedersini; C Ceconi
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

Review 3.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  H A Friedel; E M Sorkin
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

Review 4.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

5.  Intracellular calcium and ventricular function. Effects of nisoldipine on global ischemia in the isovolumic, coronary-perfused heart.

Authors:  I Amende; L A Bentivegna; A J Zeind; P Wenzlaff; W Grossman; J P Morgan
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

6.  The acute effects of intravenous nisoldipine on left ventricular function 24 to 72 hours after uncomplicated acute myocardial infarction.

Authors:  R C de Nooijer; E E van der Wall; V M Cats; G van Herpen; A van der Laarse; J A Blokland; W Jaarsma; J W Arndt; A V Bruschke
Journal:  Cardiovasc Drugs Ther       Date:  1988-12       Impact factor: 3.727

7.  Effect of lacidipine on ischaemic and reperfused isolated rabbit hearts.

Authors:  A Boraso; A Cargnoni; L Comini; G Gaia; P Bernocchi; R Ferrari
Journal:  Mol Cell Biochem       Date:  1993-08-11       Impact factor: 3.396

8.  The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man.

Authors:  J van Harten; P van Brummelen; R R Zeegers; M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

9.  A comparison of the cardioprotective effects of calcium antagonists from different classes upon ischaemic damage in the guinea-pig working heart.

Authors:  J G Hugtenburg; M J Mathy; R D Veldsema-Currie; H W Boddeke; J J Beckeringh; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.